Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Hamilton Ontario, Ontario and currently employs 102 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing radiopharmaceuticals as precision medicines. The company has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.

Industry: Biological Products, (No Diagnostic Substances) Peers: Aurinia Pharmaceuticals Inc Alpha Compute Corp Repare Therapeutics Inc. Xenon Pharmaceuticals Inc Zymeworks BC Inc.